Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinryze for Acute HAE Attacks
NCT00289211Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2005
- Primary completion
- Apr 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of c1-esterase inhibitor in hereditary angioedema (HAE) (2 arms), sponsored by Takeda. Primary endpoint: Time to Beginning of Substantial Relief of the Defining Symptom at 4 hours. Started Mar 2005; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT00289211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00289211.